Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Knockdown of Cdc25B in Renal Cell Carcinoma is Associated with Decreased Malignant Features

  • Yu, Xiu-Yue (Department of Urology, The First Hospital of China Medical University) ;
  • Zhang, Zhe (Department of Urology, The First Hospital of China Medical University) ;
  • Zhang, Guo-Jun (Department of Hematology, Shengjing Hospital of China Medical University) ;
  • Guo, Kun-Feng (Department of Urology, The First Hospital of China Medical University) ;
  • Kong, Chui-Ze (Department of Urology, The First Hospital of China Medical University)
  • Published : 2012.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Cdc25 phosphatases are important regulators of the cell cycle. Their abnormal expression detected in a number of tumors implies that their dysregulation is involved in malignant transformation. However, the role of Cdc25B in renal cell carcinomas remains unknown. To shed light on influence on renal cell carcinogenesis and subsequent progression, Cdc25B expression was examined by real-time RT-PCR and western blotting in renal cell carcinoma and normal tissues. 65 kDa Cdc25B expression was higher in carcinomas than in the adjacent normal tissues (P<0.05), positive correlations being noted with clinical stage and histopathologic grade (P<0.05). To additionally investigate the role of Cdc25B alteration in the development of renal cell carcinoma, Cdc25B siRNA was used to knockdown the expression of Cdc25B. Down-regulation resulted in slower growth, more G2/M cells, weaker capacity for migration and invasion, and induction of apoptosis in 769-P transfectants. Reduction of 14-3-3 protein expression appeared related to Cdc25B knockdown. These findings suggest an important role of Cdc25B in renal cell carcinoma development and provide a rationale for investigation of Cdc2B-based gene therapy.

Keywords

References

  1. Boutros R, Dozier C, Ducommun B (2006). The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol, 18, 185-91. https://doi.org/10.1016/j.ceb.2006.02.003
  2. Boutros R, Lobjois V, Ducommun B (2007). CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev, 7, 495-507. https://doi.org/10.1038/nrc2169
  3. Forrest A, Gabrielli B (2001). Cdc25B activity is regulated by 14-3-3. Oncogene, 20, 4393-401. https://doi.org/10.1038/sj.onc.1204574
  4. Gabrielli BG, De Souza CP, Tonks ID, et al (1996). Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci, 109, 1081-93.
  5. Gabrielli BG, Clark JM, McCormack AK, et al (1997). Hyperphosphorylation of the N-terminal domain of Cdc25 regulates activity toward cyclin B1/Cdc2 but not cyclin A/ Cdk2. J Biol Chem, 272, 28607-14. https://doi.org/10.1074/jbc.272.45.28607
  6. Giles N, Forrest A, Gabrielli B (2003). 14-3-3 acts as an intramolecular bridge to regulate cdc25B localization and activity. J Biol Chem, 278, 28580-7. https://doi.org/10.1074/jbc.M304027200
  7. Girolami F, Passerini I, Gargano D, et al (2002). Microsatellite analysis of chromosome 3p region in sporadic renal cell carcinomas. Pathol Oncol Res, 8, 241-4. https://doi.org/10.1007/BF03036738
  8. Goldstone S, Pavey S, Forrest A, et al (2001). Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. Oncogene, 20, 921-32. https://doi.org/10.1038/sj.onc.1204177
  9. Kardas I, Mrozek K, Babinska M, et al (2005). Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas. Oncol Rep, 13, 949-56.
  10. Karlsson C, Katich S, Hagting A, et al (1999). Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J Cell Biol, 146, 573-84. https://doi.org/10.1083/jcb.146.3.573
  11. Kieffer I, Lorenzo C, Dozier C, et al (2007). Differential mitotic degradation of the CDC25B phosphatase variants. Oncogene, 26, 7847-58. https://doi.org/10.1038/sj.onc.1210596
  12. Lammer C, Wagerer S, Saffrich R, et al (1998). The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J Cell Sci, 111, 2445-53.
  13. Leroy X, Zini L, Buob D, et al (2007). Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53. Arch Pathol Lab Med, 131, 102-6.
  14. Liffers ST, Munding JB, Vogt M, et al (2011). MicroRNA- 148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Invest, 91, 1472-9. https://doi.org/10.1038/labinvest.2011.99
  15. Lindqvist A, Kallstrom H, Karlsson Rosenthal C (2004). Characterisation of Cdc25B localisation and nuclear export during the cell cycle and in response to stress. J Cell Sci, 117, 4979-90. https://doi.org/10.1242/jcs.01395
  16. Loffler H, Rebacz B, Ho AD, et al (2006). Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle, 5, 2543-7. https://doi.org/10.4161/cc.5.21.3435
  17. van Vugt MA, Bras A, Medema RH (2004). Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell, 15, 799-811. https://doi.org/10.1016/j.molcel.2004.07.015
  18. Vazquez-Novelle MD, Mailand N, Ovejero S, et al (2010). Human Cdc14A phosphatase modulates the G2/M transition through Cdc25A and Cdc25B. J Biol Chem, 285, 40544-53. https://doi.org/10.1074/jbc.M110.133009
  19. Wang Z, Trope CG, Florenes VA, et al (2010). Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes. BMC Cancer, 10, 233. https://doi.org/10.1186/1471-2407-10-233
  20. Young AN, Master VA, Paner GP, Wang MD, Amin MB (2008). Renal epithelial neoplasms: diagnostic applications of gene expression profiling. Adv Anat Pathol, 15, 28-38. https://doi.org/10.1097/PAP.0b013e3181594720

Cited by

  1. Prognostic Significance of 14-3-3γ Overexpression in Advanced Non-Small Cell Lung Cancer vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3513
  2. The regulatory roles of phosphatases in cancer vol.33, pp.8, 2014, https://doi.org/10.1038/onc.2013.80
  3. High expression of Cdc25B and low expression of 14-3-3σ is associated with the development and poor prognosis in urothelial carcinoma of bladder vol.35, pp.3, 2014, https://doi.org/10.1007/s13277-013-1331-9
  4. MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells’ growth and migration vol.36, pp.7, 2015, https://doi.org/10.1007/s13277-015-3151-6
  5. Role of protein phosphatases in genitourinary cancers vol.24, pp.1, 2017, https://doi.org/10.1111/iju.13197
  6. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models vol.35, pp.7, 2016, https://doi.org/10.1038/onc.2015.126
  7. IGF2 mRNA binding protein 3 (IMP3) mediated regulation of transcriptome and translatome in glioma cells pp.1555-8576, 2017, https://doi.org/10.1080/15384047.2017.1323601
  8. Identification of genes associated with renal cell carcinoma using gene expression profiling analysis vol.12, pp.1, 2016, https://doi.org/10.3892/ol.2016.4573